The estimated Net Worth of Alfred Fu Kong Lui is at least $200 dollars as of 3 January 2022. Alfred Lui owns over 10,000 units of Emmaus Life Sciences Incorporation stock worth over $200 and over the last 3 years Alfred sold EMMA stock worth over $0.
Sign up
Alfred Lui EMMA stock SEC Form 4 insiders trading
Alfred has made over 1 trades of the Emmaus Life Sciences Incorporation stock since 2022, according to the Form 4 filled with the SEC. Most recently Alfred bought 10,000 units of EMMA stock worth $15,800 on 3 January 2022.
The largest trade Alfred's ever made was buying 10,000 units of Emmaus Life Sciences Incorporation stock on 3 January 2022 worth over $15,800. On average, Alfred trades about 10,000 units every 0 days since 2022. As of 3 January 2022 Alfred still owns at least 10,000 units of Emmaus Life Sciences Incorporation stock.
You can see the complete history of Alfred Lui stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Alfred Lui's mailing address?
Alfred's mailing address filed with the SEC is 21250 HAWTHORNE BLVD., SUITE 800, TORRANCE, CA, 90503.
Insiders trading at Emmaus Life Sciences Incorporation
Over the last 5 years, insiders at Emmaus Life Sciences Incorporation have traded over $1,625 worth of Emmaus Life Sciences Incorporation stock and bought 2,618,727 units worth $3,075,792 . The most active insiders traders include Yutaka Niihara, Willis C Lee, and Seah H. Lim. On average, Emmaus Life Sciences Incorporation executives and independent directors trade stock every 10 days with the average trade being worth of $325. The most recent stock trade was executed by Willis C Lee on 26 February 2024, trading 115,200 units of EMMA stock currently worth $14,976.
What does Emmaus Life Sciences Incorporation do?
emmaus life sciences, inc. is a biopharmaceutical company engaged in the discovery, development and commercialization of innovative treatments and therapies primarily for rare and orphan disease. we are initially focusing our product development efforts in sickle cell disease, a genetic disorder. our lead product candidate is an oral pharmaceutical grade l-glutamine treatment that demonstrated positive clinical results in our completed phase 3 clinical trial for sickle cell anemia and sickle ß0-thalassemia.
What does Emmaus Life Sciences Incorporation's logo look like?
Complete history of Alfred Lui stock trades at Emmaus Life Sciences Incorporation
Emmaus Life Sciences Incorporation executives and stock owners
Emmaus Life Sciences Incorporation executives and other stock owners filed with the SEC include:
-
Dr. Yutaka Niihara M.D., M.P.H, M.P.H.,
Chairman & CEO -
Yasushi Nagasaki CPA, CPA,
Chief Financial Officer -
Willis C. Lee M.S.,
Vice Chairman & COO -
Ian Zwicker,
Director -
Wei Peu Zen,
Director -
Jane Wood,
Director -
Masaharu Osato,
Director -
Robert Dickey,
Director -
Yasushi Nagasaki,
Interim Chief Financial Officer -
Willis Lee,
Vice Chairman of the Board, Chief Operating Officer -
Lan Tran,
President, Chief Administrative Officer -
Yutaka Niihara,
Chairman of the Board, Chief Executive Officer -
S. Steven Lee,
Independent Consultant -
Kurt H. Kruger M.B.A., M.S.,
Consultant -
Dr. Charles W. Stark Pharm.D., Pharm.D,
Sr. VP of Medical Affairs, Clinical, Regulatory -
Dale E. Short J.D.,
Gen. Counsel -
George Sekulich,
Sr. VP of Global Commercialization & Chief Information Officer -
Charles William Stark,
CSO & EVP Clinical Development -
Seah H. Lim,
Director -
Alfred Fu Kong Lui,
Director -
George Sekulich,
Co-President & CCO